Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 238-256

  Gandhi, Nishant S ^a   Tekade, Rakesh K ^a,b   Chougule, Mahavir B ^a,c  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Cancer; Clinical trial; Combination therapy; miRNA; Nanotechnology; siRNA

Indexed keywords

CHEMICAL ACTIVATION; CONTROLLED DRUG DELIVERY; DISEASES; GENE EXPRESSION; NANOTECHNOLOGY; NUCLEIC ACIDS; ONCOLOGY; RNA; TARGETED DRUG DELIVERY;

CANCER; CLINICAL TRIAL; COMBINATION THERAPY; MIRNA; SIRNA;

GENE THERAPY;

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CHITOSAN; LIPOSOME; MICRORNA; NANOCARRIER; NANOPARTICLE; SMALL INTERFERING RNA; ANGIOGENESIS INHIBITOR; DRUG CARRIER;

ANGIOGENESIS; APOPTOSIS; CANCER GENE THERAPY; CANCER RESISTANCE; CANCER THERAPY; GENE SILENCING; HUMAN; INNATE IMMUNITY; LIPOSOMAL GENE DELIVERY SYSTEM; MICELLE; NANOTECHNOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERIZATION; REVIEW; RNA INTERFERENCE; STIMULATION; ANIMAL; DRUG DELIVERY SYSTEM; NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICRORNAS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84908407738     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.001     Document Type: Review

References (233)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, D. Forman, F. Bray, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur. J. Cancer 49 (2013) (1990) 1374-1403.
2. E. Ortiz-Tudela, A. Mteyrek, A. Ballesta, P.F. Innominato, F. Levi, Cancer chronotherapeutics: experimental, theoretical, and clinical aspects, Handb. Exp. Pharmacol. (2013) 261-288.
3. R.K. Tekade, T. Dutta, A. Tyagi, A.C. Bharti, B.C. Das, N.K. Jain, Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy, J. Drug Target. 16 (2008) 758-772.
4. P.-U. Malmstrom, E. Rintala, R. Wahlqvist, P. Hellstrom, S. Hellsten, E. Hannisdal, Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial 1, J. Urol. 155 (1996) 1903-1906.
5. J.L. Steinberg, W. Yeo, S. Zhong, J.Y.H. Chan, J.S. Tam, P.K.S. Chan, N.W.Y. Leung, P.J. Johnson, Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role, J. Med. Virol. 60 (2000) 249-255.
6. W.E. Gutteridge, Existing chemotherapy and its limitations, Br. Med. Bull. 41 (1985) 162-168.
7. D.L. Lamm, A.P.M.v.d. Meijden, H. Akaza, C. Brendler, P.O. Hedlund, Y. Mizutani, T.L. Ratliff, M.R.G. Robinson, T. Shinka, Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int. J. Urol. 2 (1995) 23-35.
8. J. Sinek, H. Frieboes, X. Zheng, V. Cristini, Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles, Biomed. Microdevices 6 (2004) 297-309.
9. M. Creixell, N.A. Peppas, Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance, Nano Today 7 (2012) 367-379.
10. T.W. Hambley, The influence of structure on the activity and toxicity of Pt anticancer drugs, Coord. Chem. Rev. 166 (1997) 181-223.
11. L.J. Piddock, Multidrug-resistance efflux pumps - not just for resistance, Nat. Rev. Microbiol. 4 (2006) 629-636.
12. S. Modok, H.R. Mellor, R. Callaghan, Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer, Curr. Opin. Pharmacol. 6 (2006) 350-354.
13. M. Liscovitch, Y. Lavie, Cancer multidrug resistance: a review of recent drug discovery research, IDrugs 5 (2002) 349-355.
14. E.M. Leslie, R.G. Deeley, S.P. Cole, Multidrug resistance proteins: role of Pglycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol. Appl. Pharmacol. 204 (2005) 216-237.
15. M. Chidambaram, R. Manavalan, K. Kathiresan, Nanotherapeutics to overcome conventional cancer chemotherapy limitations, J. Pharm. Pharm. Sci. 14 (2011) 67-77.
16. R.W. Johnstone, A.A. Ruefli, S.W. Lowe, Apoptosis: a link between cancer genetics and chemotherapy, Cell 108 (2002) 153-164.
17. S. Ma, T.K. Lee, B.J. Zheng, K.W. Chan, X.Y. Guan, CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway, Oncogene 27 (2008) 1749-1758.
18. C.M. Hu, L. Zhang, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer, Biochem. Pharmacol. 83 (2012) 1104-1111.
19. S. Song, M.G. Wientjes, C. Walsh, J.L. Au, Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases, Cancer Res. 61 (2001) 6145-6150.
20. G. Kogan, J. Šandula, T.A. Korolenko, O.V. Falameeva, O.N. Poteryaeva, S.Y. Zhanaeva, O.A. Levina, T.G. Filatova, V.I. Kaledin, Increased efficiency of Lewis lung carcinoma chemotherapy with a macrophage stimulator - yeast carboxymethyl glucan, Int. Immunopharmacol. 2 (2002) 775-781.
21. F.M. Uckun, S. Ramakrishnan, L.L. Houston, Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein, Cancer Res. 45 (1985) 69-75.
22. D.C. Ihde, Chemotherapy of Lung Cancer, N. Engl. J. Med. 327 (1992) 1434-1441.
23. G. Myhr, J. Moan, Synergistic and tumour selective effects of chemotherapy and ultrasound treatment, Cancer Lett. 232 (2006) 206-213.
24. S. Filleur, A. Courtin, S. Ait-Si-Ali, J. Guglielmi, C. Merle, A. Harel-Bellan, P. Clezardin, F. Cabon, SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth, Cancer Res. 63 (2003) 3919-3922.
25. M. Manoharan, RNA interference and chemically modified small interfering RNAs, Curr. Opin. Chem. Biol. 8 (2004) 570-579.
26. J. Yano, K. Hirabayashi, S. Nakagawa, T. Yamaguchi, M. Nogawa, I. Kashimori, H. Naito, H. Kitagawa, K. Ishiyama, T. Ohgi, T. Irimura, Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer, Clin. Cancer Res. 10 (2004) 7721-7726.
27. A.A. Seyhan, RNAi: a potential new class of therapeutic for human genetic disease, Hum. Genet. 130 (2011) 583-605.
28. R.E. Yanes, J. Lu, F. Tamanoi, Chapter Nine - Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy, in: G. Feng, T. Fuyuhiko (Eds.), The Enzymes, Academic Press, 2012, pp. 185-203.
29. M.R. Fabian, N. Sonenberg, The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC, Nat. Struct. Mol. Biol. 19 (2012) 586-593.
30. P. Trang, J.B. Weidhaas, F.J. Slack, MicroRNAs as potential cancer therapeutics, Oncogene 27 (Suppl. 2) (2008) S52-S57.
31. A. Daka, D. Peer, RNAi-based nanomedicines for targeted personalized therapy, Adv. Drug Deliv. Rev. 64 (2012) 1508-1521.
32. G. Hutvágner, P.D. Zamore, RNAi: nature abhors a double-strand, Curr. Opin. Genet. Dev. 12 (2002) 225-232.
33. C.A. Sledz, B.R. Williams, RNA interference in biology and disease, Blood 106 (2005) 787-794.
34. A. de Fougerolles, H.P. Vornlocher, J. Maraganore, J. Lieberman, Interfering with disease: a progress report on siRNA-based therapeutics, Nat. Rev. Drug Discov. 6 (2007) 443-453.
35. D. Reischl, A. Zimmer, Drug delivery of siRNA therapeutics: potentials and limits of nanosystems, Nanomedicine 5 (2009) 8-20.
36. J. Winter, S. Jung, S. Keller, R.I. Gregory, S. Diederichs, Many roads to maturity: microRNA biogenesis pathways and their regulation, Nat. Cell Biol. 11 (2009) 228-234.
37. B.L. Davidson, P.B. McCray Jr., Current prospects for RNA interference-based therapies, Nat. Rev. Genet. 12 (2011) 329-340.
38. Y. Cai, X. Yu, S. Hu, J. Yu, A brief review on the mechanisms of miRNA regulation, Genomics Proteomics Bioinformatics 7 (2009) 147-154.
39. G. Tiscornia, O. Singer, M. Ikawa, I.M. Verma, A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA, Proc. Natl. Acad. Sci. 100 (2003) 1844-1848.
40. A. Judge, I. MacLachlan, Overcoming the innate immune response to small interfering RNA, Hum. Gene Ther. 19 (2008) 111-124.
41. G.R. Devi, siRNA-based approaches in cancer therapy, Cancer Gene Ther. 13 (2006) 819-829.
42. H. You, J. Jin, H. Shu, B. Yu, A.D. Milito, F. Lozupone, Y. Deng, N. Tang, G. Yao, S. Fais, J. Gu, W. Qin, Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells, Cancer Lett. 280 (2009) 110-119.
43. Small interfering RNA therapy in cancer:mechanism, potential targets, and clinical applications, Expert Opin. Ther. Targets 12 (2008) 637-645.
44. G. Di Leva, C.M. Croce, The role of microRNAs in the tumorigenesis of ovarian cancer, Front. Oncol. 3 (2013) 153.
45. M.R. Diaz, P.E. Vivas-Mejia, Nanoparticles as drug delivery systems in cancer medicine: emphasis on RNAi-containing nanoliposomes, Pharmaceuticals (Basel, Switzerland) 6 (2013) 1361-1380.
46. J.H. Taube, G.G. Malouf, E. Lu, N. Sphyris, V. Vijay, P.P. Ramachandran, K.R. Ueno, S. Gaur, M.S. Nicoloso, S. Rossi, J.I. Herschkowitz, J.M. Rosen, J.-P.J. Issa, G.A. Calin, J.T. Chang, S.A. Mani, Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties, Sci. Rep. 3 (2013).
47. E. Witsch, M. Sela, Y. Yarden, Roles for growth factors in cancer progression, Physiology (Bethesda) 25 (2010) 85-101.
48. Y. Yang, Y. Hu, Y. Wang, J. Li, F. Liu, L. Huang, Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung caner, Mol. Pharm. 9 (8) (2012) 2280-2289.
49. K.A. Whitehead, R. Langer, D.G. Anderson, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discov. 8 (2009) 129-138.
50. H. de Martimprey, C. Vauthier, C. Malvy, P. Couvreur, Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA, Eur. J. Pharm. Biopharm. 71 (2009) 490-504.
51. M.L. Yeung, Y. Bennasser, S.Y. Le, K.T. Jeang, siRNA, miRNA and HIV: promises and challenges, Cell Res. 15 (2005) 935-946.
52. P.B. Kwak, S. Iwasaki, Y. Tomari, The microRNA pathway and cancer, Cancer Sci. 101 (2010) 2309-2315.
53. J. Krol, I. Loedige, W. Filipowicz, The widespread regulation of microRNA biogenesis, function and decay, Nat. Rev. Genet. 11 (2010) 597-610.
54. D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004) 281-297.
55. A.E. Pasquinelli, MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship, Nat. Rev. Genet. 13 (2012) 271-282.
56. G.S. Mack, MicroRNA gets down to business, Nat. Biotechnol. 25 (2007) 631-638.
57. N.R. de Franca, D. Mesquita Junior, A.B. Lima, F.V. Pucci, L.E. Andrade, N.P. Silva, RNA interference: a new alternative for rheumatic diseases therapy, Rev. Bras. Reumatol. 50 (2010) 695-702.
58. S. Gao, F. Dagnaes-Hansen, E.J. Nielsen, J. Wengel, F. Besenbacher, K.A. Howard, J. Kjems, The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice, Mol. Ther. 17 (2009) 1225-1233.
59. E. Fattal, A. Bochot, State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers, Int. J. Pharm. 364 (2008) 237-248.
60. S. Akhtar, I.F. Benter, Nonviral delivery of synthetic siRNAs in vivo, J. Clin. Invest. 117 (2007) 3623-3632.
61. S. Weinstein, D. Peer, RNAi nanomedicines: challenges and opportunities within the immune system, Nanotechnology 21 (2010) 232001.
62. S. Nimesh, Recent patents in siRNA delivery employing nanoparticles as delivery vectors, Recent Pat. DNA Gene Seq. 6 (2012) 91-97.
63. J. Zhou, K.T. Shum, J.C. Burnett, J.J. Rossi, Nanoparticle-based delivery of RNAi therapeutics: progress and challenges, Pharmaceuticals (Basel, Switzerland) 6 (2013) 85-107.
64. S. Sivori, M. Falco, M. Della Chiesa, S. Carlomagno, M. Vitale, L. Moretta, A. Moretta, CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10116-10121.
65. L. Alexopoulou, A.C. Holt, R. Medzhitov, R.A. Flavell, Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3, Nature 413 (2001) 732-738.
66. K.C. Goh, M.J. deVeer, B.R. Williams, The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin, EMBO J. 19 (2000) 4292-4297.
67. R. Medzhitov, Toll-like receptors and innate immunity, Nat. Rev. Immunol. 1 (2001) 135-145.
68. A.L. Jackson, S.R. Bartz, J. Schelter, S.V. Kobayashi, J. Burchard, M. Mao, B. Li, G. Cavet, P.S. Linsley, Expression profiling reveals off-target gene regulation by RNAi, Nat. Biotechnol. 21 (2003) 635-637.
69. J. Burchard, A.L. Jackson, V. Malkov, R.H. Needham, Y. Tan, S.R. Bartz, H. Dai, A.B. Sachs, P.S. Linsley, MicroRNA-like off-target transcript regulation by siRNAs is species specific, RNA 15 (2009) 308-315.
70. D. Guzman-Villanueva, I.M. El-Sherbiny, D. Herrera-Ruiz, A.V. Vlassov, H.D. Smyth, Formulation approaches to short interfering RNA and MicroRNA: challenges and implications, J. Pharm. Sci. 101 (2012) 4046-4066.
71. H. Jung, Y. Shin, The potential RNAi-based combination therapeutics, Arch. Pharm. Res. 34 (2011) 1-2.
72. M.M. Gottesman, Mechanisms of cancer drug resistance, Annu. Rev. Med. 53 (2002) 615-627.
73. M.O. Hengartner, The biochemistry of apoptosis, Nature 407 (2000) 770-776.
74. K.L. King, J.A. Cidlowski, Cell cycle and apoptosis: common pathways to life and death, J. Cell. Biochem. 58 (1995) 175-180.
75. J.M. Adams, S. Cory, The Bcl-2 apoptotic switch in cancer development and therapy, Oncogene 26 (2007) 1324-1337.
76. C. Holohan, S. Van Schaeybroeck, D.B. Longley, P.G. Johnston, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer 13 (2013) 714-726.
77. X. Xue, X.J. Liang, Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology, Chin. J. Cancer 31 (2012) 100-109.
78. J. Satija, U. Gupta, N.K. Jain, Pharmaceutical and biomedical potential of surface engineered dendrimers, Crit. Rev. Ther. Drug Carrier Syst. 24 (2007) 257-306.
79. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J.I. Zink, A.E. Nel, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line, ACS Nano 4 (2010) 4539-4550.
80. F. Zagouri, T.N. Sergentanis, D. Chrysikos, M. Filipits, R. Bartsch, Taxanes for ovarian cancer during pregnancy: a systematic review, Oncology 83 (2012) 234-238.
81. C. Zheng, M. Zheng, P. Gong, J. Deng, H. Yi, P. Zhang, Y. Zhang, P. Liu, Y. Ma, L. Cai, Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy, Biomaterials 34 (2013) 3431-3438.
82. G. Shim, S.E. Han, Y.H. Yu, S. Lee, H.Y. Lee, K. Kim, I.C. Kwon, T.G. Park, Y.B. Kim, Y.S. Choi, C.W. Kim, Y.K. Oh, Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug, J. Control. Release 155 (2011) 60-66.
83. N. Weidner, J.P. Semple, W.R. Welch, J. Folkman, Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma, N. Engl. J. Med. 324 (1991) 1-8.
84. J. Folkman, What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82 (1990) 4-6.
85. L.A. Liotta, J. Kleinerman, G.M. Saidel, Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation, Cancer Res. 34 (1974) 997-1004.
86. J. Folkman, M. Klagsbrun, Angiogenic factors, Science (New York, N.Y.) 235 (1987) 442-447.
87. P.J. Polverini, S.J. Leibovich, Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages, Lab. Invest. 51 (1984) 635-642.
88. F. Sillman, J. Boyce, R. Fruchter, The significance of atypical vessels and neovascularization in cervical neoplasia, Am. J. Obstet. Gynecol. 139 (1981) 154-159.
89. H.M. Jensen, I. Chen, M.R. DeVault, A.E. Lewis, Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer, Science (New York, N.Y.) 218 (1982) 293-295.
90. A. Srivastava, P. Laidler, L.E. Hughes, J. Woodcock, E.J. Shedden, Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study, Eur. J. Cancer Clin. Oncol. 22 (1986) 1205-1209.
91. G.W. Chodak, C. Haudenschild, R.F. Gittes, J. Folkman, Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder, Ann. Surg. 192 (1980) 762-771.
92. C. Zhu, S. Jung, S. Luo, F. Meng, X. Zhu, T.G. Park, Z. Zhong, Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers, Biomaterials 31 (2010) 2408-2416.
93. S. Chen, X. Liu, W. Gong, H. Yang, D. Luo, X. Zuo, W. Li, P. Wu, L. Liu, Q. Xu, A. Ji, Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts, Oncol. Rep. 29 (2013) 260-268.
94. M. Ferrari, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer 5 (2005) 161-171.
95. S.F. Shi, J.F. Jia, X.K. Guo, Y.P. Zhao, D.S. Chen, Y.Y. Guo, T. Cheng, X.L. Zhang, Biocompatibility of chitosan-coated iron oxide nanoparticles with osteoblast cells, Int. J. Nanomedicine 7 (2012) 5593-5602.
96. B. Yu, Y. Zhang, W. Zheng, C. Fan, T. Chen, Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles, Inorg. Chem. 51 (2012) 8956-8963.
97. T. Osaka, T. Nakanishi, S. Shanmugam, S. Takahama, H. Zhang, Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells, Colloids Surf. B: Biointerfaces 71 (2009) 325-330.
98. D. Venturoli, B. Rippe, Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability, Am. J. Physiol. Renal Physiol. 288 (2005) F605-F613.
99. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res. 46 (1986) 6387-6392.
100. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release 65 (2000) 271-284.
101. R.A. Petros, J.M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discov. 9 (2010) 615-627.
102. K. Xiao, Y. Li, J. Luo, J.S. Lee, W. Xiao, A.M. Gonik, R.G. Agarwal, K.S. Lam, The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles, Biomaterials 32 (2011) 3435-3446.
103. S. Bai, V. Gupta, F. Ahsan, Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study, Eur. J. Pharm. Sci. 38 (2009) 165-171.
104. I. Brigger, C. Dubernet, P. Couvreur, Nanoparticles in cancer therapy and diagnosis, Adv. Drug Deliv. Rev. 54 (2002) 631-651.
105. G. Storm, S.O. Belliot, T. Daemen, D.D. Lasic, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Adv. Drug Deliv. Rev. 17 (1995) 31-48.
106. J.V. Jokerst, T. Lobovkina, R.N. Zare, S.S. Gambhir, Nanoparticle PEGylation for imaging and therapy, Nanomedicine (Lond.) 6 (2011) 715-728.
107. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, Y. Barenholz, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res. 54 (1994) 987-992.
108. Y.-P. Li, Y.-Y. Pei, X.-Y. Zhang, Z.-H. Gu, Z.-H. Zhou, W.-F. Yuan, J.-J. Zhou, J.-H. Zhu, X.-J. Gao, PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats, J. Control. Release 71 (2001) 203-211.
109. C. Fonseca, S. Simões, R. Gaspar, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J. Control. Release 83 (2002) 273-286.
110. M. Tobio, R. Gref, A. Sanchez, R. Langer, M.J. Alonso, Stealth PLA-PEG nanoparticles as protein carriers for nasal administration, Pharm. Res. 15 (1998) 270-275.
111. Y. Dong, S.-S. Feng, Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs, Biomaterials 25 (2004) 2843-2849.
112. J. Yang, S.B. Park, H.-G. Yoon, Y.M. Huh, S. Haam, Preparation of poly ε-caprolactone nanoparticles containing magnetite for magnetic drug carrier, Int. J. Pharm. 324 (2006) 185-190.
113. J.S. Chawla, M.M. Amiji, Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen, Int. J. Pharm. 249 (2002) 127-138.
114. M. Gou, L. Zheng, X. Peng, K. Men, X. Zheng, S. Zeng, G. Guo, F. Luo, X. Zhao, L. Chen, Y. Wei, Z. Qian, Poly(ε-caprolactone) - poly(ethylene glycol) - poly(ε-caprolactone) (PCL - PEG - PCL) nanoparticles for honokiol delivery in vitro, Int. J. Pharm. 375 (2009) 170-176.
115. S.D. Swanson, J.F. Kukowska-Latallo, A.K. Patri, C. Chen, S. Ge, Z. Cao, A. Kotlyar, A.T. East, J.R. Baker, Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement, Int. J. Nanomedicine 3 (2008) 201-210.
116. T.P. Thomas, A.K. Patri, A. Myc, M.T. Myaing, J.Y. Ye, T.B. Norris, J.R. Baker, In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles†, Biomacromolecules 5 (2004) 2269-2274.
117. S. Santra, P. Zhang, K. Wang, R. Tapec, W. Tan, Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers, Anal. Chem. 73 (2001) 4988-4993.
118. M. Qhobosheane, S. Santra, P. Zhang, W. Tan, Biochemically functionalized silica nanoparticles, Analyst 126 (2001) 1274-1278.
119. C. Kneuer, M. Sameti, E.G. Haltner, T. Schiestel, H. Schirra, H. Schmidt, C.-M. Lehr, Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA, Int. J. Pharm. 196 (2000) 257-261.
120. Y. Wu, M. Crawford, Y. Mao, R.J. Lee, I.C. Davis, T.S. Elton, L.J. Lee, S.P. Nana-Sinkam, Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer, Mol. Ther. Nucleic Acids 2 (2013) e84.
121. A. Schade, E. Delyagina, D. Scharfenberg, A. Skorska, C. Lux, R. David, G. Steinhoff, Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles, Int. J. Mol. Sci. 14 (2013) 10710-10726.
122. C.J. Cheng, W.M. Saltzman, Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing, Mol. Pharm. 9 (2012) 1481-1488.
123. J. Conde, J.T. Dias, V. Grazu, M. Moros, P.V. Baptista, J.M. de la Fuente, Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine, Front. Chem. 2 (2014) 48.
124. Z.P. Xu, Q.H. Zeng, G.Q. Lu, A.B. Yu, Inorganic nanoparticles as carriers for efficient cellular delivery, Chem. Eng. Sci. 61 (2006) 1027-1040.
125. T. Kim, T. Hyeon, Applications of inorganic nanoparticles as therapeutic agents, Nanotechnology 25 (2014) 012001.
126. V. Sokolova, M. Epple, Inorganic nanoparticles as carriers of nucleic acids into cells, Angew. Chem. Int. Ed Engl. 47 (2008) 1382-1395.
127. E. Casals, V.F. Puntes, Inorganic nanoparticle biomolecular corona: formation, evolution and biological impact, Nanomedicine (Lond.) 7 (2012) 1917-1930.
128. D.R. Radu, C.Y. Lai, K. Jeftinija, E.W. Rowe, S. Jeftinija, V.S. Lin, A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent, J. Am. Chem. Soc. 126 (2004) 13216-13217.
129. A.M. Chen, M. Zhang, D. Wei, D. Stueber, O. Taratula, T. Minko, H. He, Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells, Small 5 (2009) 2673-2677.
130. P. Borm, F.C. Klaessig, T.D. Landry, B. Moudgil, J. Pauluhn, K. Thomas, R. Trottier, S. Wood, Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles, Toxicol. Sci. 90 (2006) 23-32.
131. K.S. Finnie, D.J. Waller, F.L. Perret, A.M. Krause-Heuer, H.Q. Lin, J.V. Hanna, C.J. Barbé, Biodegradability of sol-gel silica microparticles for drug delivery, J. Sol-Gel Sci. Technol. 49 (2008) 12-18.
132. I.I. Slowing, B.G. Trewyn, V.S. Lin, Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins, J. Am. Chem. Soc. 129 (2007) 8845-8849.
133. D.M. Huang, Y. Hung, B.S. Ko, S.C. Hsu, W.H. Chen, C.L. Chien, C.P. Tsai, C.T. Kuo, J.C. Kang, C.S. Yang, C.Y. Mou, Y.C. Chen, Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking, FASEB J. 19 (2005) 2014-2016.
134. Y.-S. Lin, C.-P. Tsai, H.-Y. Huang, C.-T. Kuo, Y. Hung, D.-M. Huang, Y.-C. Chen, C.-Y. Mou, Well-ordered mesoporous silica nanoparticles as cell markers, Chem. Mater. 17 (2005) 4570-4573.
135. O. Taratula, O.B. Garbuzenko, A.M. Chen, T. Minko, Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA, J. Drug Target. 19 (2011) 900-914.
136. H. Meng, W.X. Mai, H. Zhang, M. Xue, T. Xia, S. Lin, X. Wang, Y. Zhao, Z. Ji, J.I. Zink, A. E. Nel, Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo, ACS Nano 7 (2013) 994-1005.
137. W. Wei, P.P. Lv, X.M. Chen, Z.G. Yue, Q. Fu, S.Y. Liu, H. Yue, G.H. Ma, Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression, Biomaterials 34 (2013) 3912-3923.
138. S. Biswas, P.P. Deshpande, G. Navarro, N.S. Dodwadkar, V.P. Torchilin, Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery, Biomaterials 34 (2013) 1289-1301.
139. T.L. Kaneshiro, Z.R. Lu, Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier, Biomaterials 30 (2009) 5660-5666.
140. Y. Chen, S.R. Bathula, J. Li, L. Huang, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer, J. Biol. Chem. 285 (2010) 22639-22650.
141. Y. Chen, J.J. Wu, L. Huang, Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy, Mol. Ther. 18 (2010) 828-834.
142. M. Saad, O.B. Garbuzenko, T. Minko, Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer, Nanomedicine (Lond.) 3 (2008) 761-776.
143. S.H. Kang, H.J. Cho, G. Shim, S. Lee, S.H. Kim, H.G. Choi, C.W. Kim, Y.K. Oh, Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy, Pharm. Res. 28 (2011) 3069-3078.
144. Y.L. Jang, U.J. Yun, M.S. Lee, M.G. Kim, S. Son, K. Lee, S.Y. Chae, D.W. Lim, H.T. Kim, S. H. Kim, J.H. Jeong, Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression, Int. J. Pharm. 434 (2012) 488-493.
145. D. Cheng, N. Cao, J. Chen, X. Yu, X. Shuai, Multifunctional nanocarrier mediated codelivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat, Biomaterials 33 (2012) 1170-1179.
146. Y.B. Patil, S.K. Swaminathan, T. Sadhukha, L. Ma, J. Panyam, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance, Biomaterials 31 (2010) 358-365.
147. Y.H. Yu, E. Kim, D.E. Park, G. Shim, S. Lee, Y.B. Kim, C.W. Kim, Y.K. Oh, Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA, Eur. J. Pharm. Biopharm. 80 (2012) 268-273.
148. T.M. Sun, J.Z. Du, Y.D. Yao, C.Q. Mao, S. Dou, S.Y. Huang, P.Z. Zhang, K.W. Leong, E.W. Song, J. Wang, Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression, ACS Nano 5 (2011) 1483-1494.
149. K. Nakamura, A.S. Abu Lila, M. Matsunaga, Y. Doi, T. Ishida, H. Kiwada, A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA, Mol. Ther. 19 (2011) 2040-2047.
150. Q. Yin, J. Shen, L. Chen, Z. Zhang, W. Gu, Y. Li, Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters), Biomaterials 33 (2012) 6495-6506.
151. Y. Chen, X. Zhu, X. Zhang, B. Liu, L. Huang, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy, Mol. Ther. 18 (2010) 1650-1656.
152. L.S. Jabr-Milane, L.E. van Vlerken, S. Yadav, M.M. Amiji, Multi-functional nanocarriers to overcome tumor drug resistance, Cancer Treat. Rev. 34 (2008) 592-602.
153. J. Li, Y. Yang, L. Huang, Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor, J. Control. Release 158 (2012) 108-114.
154. J. Li, Y.C. Chen, Y.C. Tseng, S. Mozumdar, L. Huang, Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery, J. Control. Release 142 (2010) 416-421.
155. B.F. Canine, A. Hatefi, Development of recombinant cationic polymers for gene therapy research, Adv. Drug Deliv. Rev. 62 (2010) 1524-1529.
156. S.S. Mangipudi, B.F. Canine, Y. Wang, A. Hatefi, Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells, Mol. Pharm. 6 (2009) 1100-1109.
157. B.F. Canine, Y. Wang, W. Ouyang, A. Hatefi, Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus, J. Control. Release 151 (2011) 95-101.
158. Y. Chen, H. Chen, J. Shi, Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells, Mol. Pharm. 11 (2013) 2495-2510.
159. H. Ragelle, G. Vandermeulen, V. Preat, Chitosan-based siRNA delivery systems, J. Control. Release 172 (2013) 207-218.
160. L. Hu, Y. Sun, Y. Wu, Advances in chitosan-based drug delivery vehicles, Nanoscale 5 (2013) 3103-3111.
161. P.P. Lv, W. Wei, H. Yue, T.Y. Yang, L.Y. Wang, G.H. Ma, Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration, Biomacromolecules 12 (2011) 4230-4239.
162. K.A. Janes, M.P. Fresneau, A. Marazuela, A. Fabra, M.a.J. Alonso, Chitosan nanoparticles as delivery systems for doxorubicin, J. Control. Release 73 (2001) 255-267.
163. K.M. Varum, M.M. Myhr, R.J. Hjerde, O. Smidsrod, In vitro degradation rates of partially N-acetylated chitosans in human serum, Carbohydr. Res. 299 (1997) 99-101.
164. K. Nagpal, S.K. Singh, D.N. Mishra, Chitosan nanoparticles: a promising system in novel drug delivery, Chem. Pharm. Bull. 58 (2010) 1423-1430.
165. J.J. Wang, Z.W. Zeng, R.Z. Xiao, T. Xie, G.L. Zhou, X.R. Zhan, S.L. Wang, Recent advances of chitosan nanoparticles as drug carriers, Int. J. Nanomedicine 6 (2011) 765-774.
166. A.A. Badawi, H.M. El-Laithy, R.K. El Qidra, H. El Mofty, M. El dally, Chitosan based nanocarriers for indomethacin ocular delivery, Arch. Pharm. Res. 31 (2008) 1040-1049.
167. L. Boji, M. Linan, S. Juan, J. Weiwei, W. Minjie, S. Xianzheng, Biocompatibility assessment of porous chitosan-nafion and chitosan-PTFE composites in vivo, J. Biomed. Mater. Res. A 102 (6) (2013) 2055-2060.
168. A.W. Bosman, H.M. Janssen, E.W. Meijer, About dendrimers: structure, physical properties, and applications, Chem. Rev. 99 (1999) 1665-1688.
169. A. Tomalia, D.H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, P. Smith, A new class of polymers: starburst-dendritic macromolecules, Polym. J. 17 (1985) 117-132.
170. R.M. Crooks, M. Zhao, L. Sun, V. Chechik, L.K. Yeung, Dendrimer-encapsulated metal nanoparticles: synthesis, characterization, and applications to catalysis, Acc. Chem. Res. 34 (2000) 181-190.
171. P. Dwivedi, R.K. Tekade, N.K. Jain, Nanoparticulate Carrier Mediated Intranasal Delivery of Insulin for the Restoration of Memory Signaling in Alzheimer's Disease, Curr. Nanosci. 9 (2013) 46-55.
172. K. Madaan, S. Kumar, N. Poonia, V. Lather, D. Pandita, Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues, J. Pharm. Bioallied Sci. 6 (2014) 139-150.
173. Z. Zhou, A. D'Emanuele, D. Attwood, Solubility enhancement of paclitaxel using a linear-dendritic block copolymer, Int. J. Pharm. 452 (2013) 173-179.
174. J. Alper, Rising chemical "stars" could play many roles, Science (New York, N.Y.) 251 (1991) 1562-1564.
175. O. Taratula, O.B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V.P. Pozharov, H. He, T. Minko, Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery, J. Control. Release 140 (2009) 284-293.
176. B.F. Canine, Y. Wang, W. Ouyang, A. Hatefi, Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus, J. Control. Release 151 (2011) 95-101.
177. H. Kulhari, D. Pooja, S.K. Prajapati, A.S. Chauhan, Performance evaluation of PAMAM dendrimer based simvastatin formulations, Int. J. Pharm. 405 (2011) 203-209.
178. G. Thiagarajan, K. Greish, H. Ghandehari, Charge affects the oral toxicity of poly(amidoamine) dendrimers, Eur. J. Pharm. Biopharm. 84 (2013) 330-334.
179. S.H. Kim, J.H. Jeong, S.H. Lee, S.W. Kim, T.G. Park, Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer, J. Control. Release 129 (2008) 107-116.
180. K. Itaka, K. Kataoka, Progress and prospects of polyplex nanomicelles for plasmid DNA delivery, Curr. Gene Ther. 11 (2011) 457-465.
181. S.R. Croy, G.S. Kwon, Polymeric micelles for drug delivery, Curr. Pharm. Des. 12 (2006) 4669-4684.
182. J. Deng, N. Gao, Y. Wang, H. Yi, S. Fang, Y. Ma, L. Cai, Self-assembled cationic micelles based on PEG-PLL-PLLeu hybrid polypeptides as highly effective gene vectors, Biomacromolecules 13 (2012) 3795-3804.
183. P. van de Wetering, J.Y. Cherng, H. Talsma, D.J. Crommelin, W.E. Hennink, 2-(Dimethylamino)ethyl methacrylate based (co)polymers as gene transfer agents, J. Control. Release 53 (1998) 145-153.
184. Y.Z. You, D.S. Manickam, Q.H. Zhou,D. Oupicky, Reducible poly(2-dimethylaminoethyl methacrylate): synthesis, cytotoxicity, and gene delivery activity, J. Control. Release 122 (2007) 217-225.
185. S. Zou, N. Cao, D. Cheng, R. Zheng, J. Wang, K. Zhu, X. Shuai, Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin, Int. J. Nanomedicine 7 (2012) 3823-3835.
186. J. Guo, A.M. O'Mahony, W.P. Cheng, C.M. O'Driscoll, Amphiphilic polyallylamine based polymeric micelles for siRNA delivery to the gastrointestinal tract: in vitro investigations, Int. J. Pharm. 447 (2013) 150-157.
187. S. Zeng, M.P. Xiong, Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1), Biomaterials 34 (2013) 6882-6892.
188. T.M. Allen, P.R. Cullis, Liposomal drug delivery systems: From concept to clinical applications, Advanced drug delivery reviews 65 (2013) 36-48.
189. V.P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov. 4 (2005) 145-160.
190. S. Mallick, J.S. Choi, Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery, J. Nanosci. Nanotechnol. 14 (2014) 755-765.
191. Y. Chen, J. Sen, S.R. Bathula, Q. Yang, R. Fittipaldi, L. Huang, Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells, Mol. Pharm. 6 (2009) 696-705.
192. S.D. Li, Y.C. Chen, M.J. Hackett, L. Huang, Tumor-targeted delivery of siRNA by self-assembled nanoparticles, Mol. Ther. 16 (2008) 163-169.
193. M.S. Suh, G. Shim, H.Y. Lee, S.E. Han, Y.H. Yu, Y. Choi, K. Kim, I.C. Kwon, K.Y. Weon, Y.B. Kim, Y.K. Oh, Anionic amino acid-derived cationic lipid for siRNA delivery, J. Control. Release 140 (2009) 268-276.
194. M. Neu, D. Fischer, T. Kissel, Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives, J. Gene Med. 7 (2005) 992-1009.
195. H.R. Kim, I.K. Kim, K.H. Bae, S.H. Lee, Y. Lee, T.G. Park, Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA, Mol. Pharm. 5 (2008) 622-631.
196. P. Trang, J.F. Wiggins, C.L. Daige, C. Cho, M. Omotola, D. Brown, J.B. Weidhaas, A.G. Bader, F.J. Slack, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol. Ther. 19 (2011) 1116-1122.
197. Y. Malam, M. Loizidou, A.M. Seifalian, Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer, Trends Pharmacol. Sci. 30 (2009) 592-599.
198. S. Nimesh, A. Goyal, V. Pawar, S. Jayaraman, P. Kumar, R. Chandra, Y. Singh, K.C. Gupta, Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells, J. Control. Release 110 (2006) 457-468.
199. S.J. Sung, S.H. Min, K.Y. Cho, S. Lee, Y.J. Min, Y.I. Yeom, J.K. Park, Effect of polyethylene glycol on gene delivery of polyethylenimine, Biol. Pharm. Bull. 26 (2003) 492-500.
200. D. Goula, C. Benoist, S. Mantero, G. Merlo, G. Levi, B.A. Demeneix, Polyethylenimine-based intravenous delivery of transgenes to mouse lung, Gene Ther. 5 (1998) 1291-1295.
201. A. Akinc, M. Thomas, A.M. Klibanov, R. Langer, Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis, J. Gene Med. 7 (2005) 657-663.
202. S. Yang, S. May, Release of cationic polymer-DNA complexes fromthe endosome: A theoretical investigation of the proton sponge hypothesis, J. Chem. Phys. 129 (2008) 185105.
203. F.M. Orson, B.M. Kinsey, P.J. Hua, B.S. Bhogal, C.L. Densmore, M.A. Barry, Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses, J. Immunol. 164 (2000) (1950) 6313-6321.
204. S.V. Vinogradov, T.K. Bronich, A.V. Kabanov, Self-assembly of polyaminepoly( ethylene glycol) copolymers with phosphorothioate oligonucleotides, Bioconjug. Chem. 9 (1998) 805-812.
205. P. Erbacher, T. Bettinger, P. Belguise-Valladier, S. Zou, J.L. Coll, J.P. Behr, J.S. Remy, Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), J. Gene Med. 1 (1999) 210-222.
206. O. Boussif, F. Lezoualc'h, M.A. Zanta, M.D. Mergny, D. Scherman, B. Demeneix, J.P. Behr, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7297-7301.
207. S.Y. Chae, H.J. Kim, M.S. Lee, Y.L. Jang, Y. Lee, S.H. Lee, K. Lee, S.H. Kim, H.T. Kim, S.C. Chi, T.G. Park, J.H. Jeong, Energy-independent intracellular gene delivery mediated by polymeric biomimetics of cell-penetrating peptides, Macromol. Biosci. 11 (2011) 1169-1174.
208. N. Cao, D. Cheng, S. Zou, H. Ai, J. Gao, X. Shuai, The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells, Biomaterials 32 (2011) 2222-2232.
209. H.Y. Huang, W.T. Kuo, M.J. Chou, Y.Y. Huang, Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression, J. Biomed. Mater. Res. A 97 (2011) 330-338.
210. A. Patel, M. Patel, X. Yang, A.K. Mitra, Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles, Protein Pept. Lett. (2014).
211. F.R. Wurm, C.K. Weiss, Nanoparticles from renewable polymers, Front. Chem. 2 (2014) 49.
212. C.Z. Wang, Y.C. Fu, S.C. Jian, Y.H. Wang, P.L. Liu, M.L. Ho, C.K. Wang, Synthesis and characterization of cationic polymeric nanoparticles as simvastatin carriers for enhancing the osteogenesis of bone marrow mesenchymal stem cells, J. Colloid Interface Sci. 432 (2014) 190-199.
213. J. Panyam, J. Lof, E. O'Leary, V. Labhasetwar, Efficiency of Dispatch and Infiltrator cardiac infusion catheters in arterial localization of nanoparticles in a porcine coronary model of restenosis, J. Drug Target. 10 (2002) 515-523.
214. J. Panyam, S.K. Sahoo, S. Prabha, T. Bargar, V. Labhasetwar, Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L-lactide-coglycolide) nanoparticles, Int. J. Pharm. 262 (2003) 1-11.
215. Y. Patil, J. Panyam, Polymeric nanoparticles for siRNA delivery and gene silencing, Int. J. Pharm. 367 (2009) 195-203.
216. G. Nishimura, S. Yanoma, H. Mizuno, K. Satake, T. Taguchi, Y. Ikeda, M. Tsukuda, Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells, Cancer Lett. 159 (2000) 1-7.
217. D.J. Jere, C.S. Cho, Biodegradable polymer-mediated sh/siRNA delivery for cancer studies, Methods Mol. Biol. 623 (2010) 243-269.
218. A. Ramasubramanian, S. Shiigi, G.K. Lee, F. Yang, Non-viral delivery of inductive and suppressive genes to adipose-derived stem cells for osteogenic differentiation, Pharm. Res. 28 (2011) 1328-1337.
219. A. Kumari, S.K. Yadav, S.C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids Surf. B: Biointerfaces 75 (2010) 1-18.
220. C.J. Tighe, R.Q. Cabrera, R.I. Gruar, J.A. Darr, Scale up production of nanoparticles: continuous supercritical water synthesis of Ce-Zn oxides, Ind. Eng. Chem. Res. 52 (2013) 5522-5528.
221. H.E. Colley, V. Hearnden, M. Avila-Olias, D. Cecchin, I. Canton, J. Madsen, S. MacNeil, N. Warren, K. Hu, J.A. McKeating, S.P. Armes, C. Murdoch, M.H. Thornhill, G. Battaglia, Polymersome-Mediated Delivery of Combination Anticancer Therapy to Head and Neck Cancer Cells: 2D and 3D in Vitro Evaluation, Molecular pharmaceutics 11 (2014) 1176-1188.
222. Y. Kim, M. Tewari, J.D. Pajerowski, S. Cai, S. Sen, J.H. Williams, S.R. Sirsi, G.J. Lutz, D. E. Discher, Polymersome delivery of siRNA and antisense oligonucleotides, J. Control. Release 134 (2009) 132-140.
223. E. Lorenceau, A.S. Utada, D.R. Link, G. Cristobal, M. Joanicot, D.A. Weitz, Generation of polymerosomes from double-emulsions, Langmuir 21 (2005) 9183-9186.
224. R. Rastogi, S. Anand, V. Koul, Evaluation of pharmacological efficacy of 'insulin-surfoplex' encapsulated polymer vesicles, Int. J. Pharm. 373 (2009) 107-115.
225. H.O. Kim, E. Kim, Y. An, J. Choi, E. Jang, E.B. Choi, A. Kukreja, M.H. Kim, B. Kang, D.J. Kim, J.S. Suh, Y.M. Huh, S. Haam, A biodegradable polymersome containing Bcl-xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect, Macromol. Biosci. 13 (2013) 745-754.
226. M. Li, S. Lv, Z. Tang, W. Song, H. Yu, H. Sun, H. Liu, X. Chen, Polypeptide/doxorubicin hydrochloride polymersomes prepared through organic solvent-free technique as a smart drug delivery platform, Macromol. Biosci. 13 (2013) 1150-1162.
227. D.A. Christian, S. Cai, D.M. Bowen, Y. Kim, J.D. Pajerowski, D.E. Discher, Polymersome carriers: from self-assembly to siRNA and protein therapeutics, Eur. J. Pharm. Biopharm. 71 (2009) 463-474.
228. T.O. Pangburn, K. Georgiou, F.S. Bates, E. Kokkoli, Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression, Langmuir 28 (2012) 12816-12830.
229. F. Ahmed, R.I. Pakunlu, G. Srinivas, A. Brannan, F. Bates, M.L. Klein, T. Minko, D.E. Discher, Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation, Mol. Pharm. 3 (2006) 340-350.
230. W.H. De Jong, P.J. Borm, Drug delivery and nanoparticles:applications and hazards, Int. J. Nanomedicine 3 (2008) 133-149.
231. S.H. Medina, M.E. El-Sayed, Dendrimers as carriers for delivery of chemotherapeutic agents, Chem. Rev. 109 (2009) 3141-3157.
232. J.C. Burnett, J.J. Rossi, K. Tiemann, Current progress of siRNA/shRNA therapeutics in clinical trials, Biotechnol. J. 6 (2011) 1130-1146.
233. J.A. Gollob, ALN-VSP02 Phase 1 Trial Update Demonstrating RNAi in Man, 2011..